Systemic Lupus Erythematosus: References

1. Aringer M, Smolen JS. Tumor necrosis factor and other pro–inflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus. 2004;13:344–347.

2. Kettler DB. Can manipulation of the ratios of essential fatty acids slow the rapid rate of postmenopausal bone loss? Altern Med Rev. 2001;6:61–77.

3. Clark WF, Kortas C, Heidenheim AP, Garland J, Spanner E, Parbtani A. Flaxseed in lupus nephritis: a two–year nonplacebo–controlled crossover study.
J Am Coll Nutr. 2001;20:143–148.

4. Clark WF, Parbtani A, Huff MW, et al. Flaxseed: a potential treatment for lupus nephritis. Kidney Int. 1995;48:475–480.

5. Walton AJ, Snaith ML, Locniskar M, Cumberland AG, Morrow WJ, Isenberg DA. Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis. 1991;50:463–466.

6. Ilowite NT, Copperman N, Leicht T, Kwong T, Jacobson MS. Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol. 1995;22:1347–1351.

7. Comstock GW, Burke AE, Hoffman SC, et al. Serum concentrations of alpha tocopherol, beta–carotene, and retinol preceding the diagnosis of rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis. 1997;56:323–325.

8. Alves JD, Grima B. Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep. 2003;5:383–390.

9. Kovacic P, Jacintho JD. Systemic lupus erythematosus and other autoimmune diseases from endogenous and exogenous agents: unifying theme of oxidative stress. Mini Rev Med Chem. 2003;3:568–575.

10. Stefanescu M, Matache C, Onu A, et al. Pycnogenol efficacy in the treatment of systemic lupus erythematosus patients. Phytother Res. 2001;15:698–704.

11. Tam LS, Li EK, Leung VY, et al. Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double–blind, placebo–controlled pilot study. J Rheumatol. 2005;32:275–282.

12. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J. Elevated triglycerides and low levels of high–density lipoprotein as markers of disease activity in association with up–regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 2003;48:2533–2540.

13. Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford). 2004;43:924–929.

14. Shah M, Coyle Y, Kavanaugh A, Adams–Huet B, Lipsky PE. Development and initial evaluation of a culturally sensitive cholesterol–lowering diet program for Mexican and African American patients with systemic lupus erythematosus.
Arthritis Care Res. 2000;13:205–212.

15. Di Munno O, Mazzantini M, Delle Sedie A, Mosca M, Bombardieri S. Risk factors for osteoporosis in female patients with systemic lupus erythematosus. Lupus. 2004;13:724–730.

16. Warady BD, Lindsley CB, Robinson FG, Lukert BP. Effects of nutritional supplementation on bone mineral status of children with rheumatic diseases receiving corticosteroid therapy. J Rheumatol. 1994;21:530–535.

17. Petri MA, Mease PJ, Merrill JT, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004;50:2858–2868.

18. Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild–to–moderate systemic lupus erythematosus: a multicenter randomized, double–blind, placebo–controlled trial. Arthritis Rheum. 2002;46:2924–2927.